Advertisement

The Metabolism of Antiparasitic Drugs and Pharmacogenetics in African Populations: From Molecular Mechanisms to Clinical Applications

  • Collen Masimirembwa
Chapter
First Online:

Abstract

We characterised over 20 antiparasitic drugs with respect to the enzymes responsible for their metabolism. We showed that CYP2C8 is responsible for the metabolism of amodiaquine (ADQ) to desethylamodiaquine and identified a novel reactive metabolite catalysed by extrahepatic CYP1A1 and CYPIB1 which is giving us insights into possible ways of synthesising safer analogues of ADQ. Praziquantel (PZQ) was shown to be metabolised by CYP1A2 and 3A4, knowledge which is being used to explore the possibility of coadministering PZQ with known inhibitors of these enzymes in order to increase its bioavailability. From evaluating over 30 antiparasitic drugs for inhibition of major drug metabolising enzymes, 10 were shown to be potent inhibitors with a potential risk to cause metabolism based drug–drug interactions. The inhibitory effects of artemisinin and thiabendazole on CYP1A2 where further investigated in vivo and the effect of thiabedazole resulted in clinically relevant drug–drug interactions. We studied the genetic polymorphism of drug metabolising enzymes in African populations. We screened genes of 8 drug metabolising enzymes (CYP2B6, 2C9, 2C19, 2D6, FMO, NAT-2, GSTT and GSTM) for over 15 single nucleotide polymorphisms (SNPs) in 9 ethnic groups from across Africa (Ibo, Hausa and Yoruba of Nigeria, Luo, Kikuyu and Masai of Kenya, mixed Bantu volunteers from Tanzania, the Venda of South Africa, the Shona and San of Zimbabwe). Multivariate cluster analysis showed that Caucausian, Oriental and African populations show differential cluster groups, an indication that these major population groups are likely to metabolically handle medicines differently. Further studies led to the discovery of new genetic variants unique to populations of African origin such as CYP2D6*17. Clinical studies on the metabolism and elimination of efavirenz by the polymorphic CYP2B6 showed that African populations had a reduced capacity to dispose efavirenz and that patients homozygous for the CYP2B6*6 variant would require as low as half the dose given to Europeans to achieve the same safe and efficacious concentrations.

Keywords

Adverse Drug Reaction African Population Drug Metabolise Enzyme Antiparasitic Drug Research Capacity Strengthen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

We acknowledge funding from ISP, WHO–TDR, and EU that supports the work in our laboratory. We acknowledge the long term scientific and technical support from AstraZeneca that has resulted in AiBST having world class expertise in DMPK. We also acknowledge the many international collaborators, AiBST scientists, and students whose vision and hard work have resulted in the work presented in this chapter.

References

  1. 1.
    Akililu E, Dandara C, Bertilsson L et al (2007) Pharmacogenetics of cytochrome P450s in African populations: clinical and molecular evolutionary implications. In: Suarez-Kurtz G (ed) Pharmacogenomics in admixed populations, Ed. Landes Bioscience, Germany (ISBN 978-1-58706-130-9)Google Scholar
  2. 2.
    Bapiro TE, Egnell AC, Hasler JA et al (2001) Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 29:30–35Google Scholar
  3. 3.
    Bapiro T, Hasler JA, Ridderström M et al (2002) The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6*17 variant. Implications for CYP2D6 phenotyping studies and the clinical use of substrate drugs in some African populations. Biochem Pharmacol 7422:1–12Google Scholar
  4. 4.
    Bapiro TE, Sayi J, Hasler JA et al (2005) Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans. Eur J Clin Pharmacol 61:755–761CrossRefGoogle Scholar
  5. 5.
    Castro N, Jung H, Medina R et al (2002) Interaction between Grapefruit Juice and Praziquantel in Humans. Antimicrob Agents Chemother 46:1614–1616CrossRefGoogle Scholar
  6. 6.
    Dandara C, Masimirembwa C, Magimba A et al (2002) Arylamine N-acetyltransferase (NAT2) genotypes in Africans: the identification of a new allele with nucleotide changes 481C > T and 590 > A. Pharmacogenetics 12:1–4CrossRefGoogle Scholar
  7. 7.
    Dandara C, Masimirembwa CM, Magimba A et al (2001) Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol 57:11–17CrossRefGoogle Scholar
  8. 8.
    Dandara C, Sayi J, Masimirembwa CM et al (2002) Genetic polymorphism of cytochrome P450 1A1 (Cyp1A1) and glutathione transferases (M1, T1 and P1) among Africans. Clin Chem Lab Med 40:952–957CrossRefGoogle Scholar
  9. 9.
    Johansson T, Jurva U, Grönberg G et al (2009) Novel metabolites of amodiaquine formed by CYP1A1 and CYP1B1: structure elucidation using electrochemistry, mass spectrometry, and NMR. Drug Metab Dispos 37:571–579CrossRefGoogle Scholar
  10. 10.
    Jurva U, Holmén A, Grönberg G et al (2008) Electrochemical generation of electrophilic drug metabolites: characterization of amodiaquine quinoneimine and cysteinyl conjugates by MS, IR, and NMR. Chem Res Toxicol 21:928–935CrossRefGoogle Scholar
  11. 11.
    Keogh A, Spratt P, McCosker C et al (1995) Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 333:628–663CrossRefGoogle Scholar
  12. 12.
    Lew G, Murray WE, Lane JR et al (1989) Theophylline-thiabendazole drug interaction. Clin Pharm 8:225–227Google Scholar
  13. 13.
    Li XQ, Björkman A, Andersson TB et al (2002) Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 300:399–407CrossRefGoogle Scholar
  14. 14.
    Li XQ, Björkman A, Andersson TB et al (2003) Identification of human cytochrome P(450)s that metabolise antiparasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59:429–442CrossRefGoogle Scholar
  15. 15.
    Mao M, Matimba A, Scordo MG et al (2009) Flavin-containing monooxygenase 3 polymorphisms in 13 ethnic populations from Europe, East Asia and sub-Saharan Africa: frequency and linkage analysis. Pharmacogenomics 10:1447–1455CrossRefGoogle Scholar
  16. 16.
    Masimirembwa C, Bertilsson L, Johansson I et al (1995) Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 57:656–661CrossRefGoogle Scholar
  17. 17.
    Masimirembwa C, Hasler JA, Bertilsson L et al (1996) Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population: reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 51:117–122CrossRefGoogle Scholar
  18. 18.
    Masimirembwa C, Persson I, Bertilsson L et al (1996) A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 42:713–719CrossRefGoogle Scholar
  19. 19.
    Masimirembwa CM, Bredberg U, Andersson TB (2003) Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin Pharmacokinet 42:515–528CrossRefGoogle Scholar
  20. 20.
    Masimirembwa CM, Dandara C, Sommers DK et al (1998) Genetic polymorphism of cytochrome P4501A1, microsomal epoxide hydrolase, and glutathione S-transferases M1 and T1 in Zimbabweans and Venda of southern Africa. Pharmacogenetics 18:83–85CrossRefGoogle Scholar
  21. 21.
    Masimirembwa CM, Gustafsson LL, Dahl ML et al (1996) Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes. Br J Clin Pharmacol 41:344–346CrossRefGoogle Scholar
  22. 22.
    Masimirembwa CM, Hasler JA (1994) Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors. Biochem Pharmacol 48:1779–1783CrossRefGoogle Scholar
  23. 23.
    Masimirembwa CM, Hasler JA (1997) Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants. Brain Res Bull 44:561–571CrossRefGoogle Scholar
  24. 24.
    Masimirembwa CM, Hasler JA, Johansson I (1995) Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6. Eur J Clin Pharmacol 48:35–38Google Scholar
  25. 25.
    Masimirembwa CM, Ridderström M, Zamora I et al (2003) Combining pharmacophore and protein modeling to predict CYP450 inhibitors and substrates. Methods Enzymol 357:133–144CrossRefGoogle Scholar
  26. 26.
    Masimirembwa CM, Thompson R, Andersson TB (2001) In vitro high throughput screening of compounds for favourable metabolic properties in drug discovery. Comb Chem High Throughput Screen 4:245–263Google Scholar
  27. 27.
    Matimba A, Del-Favero J, Van Broeckhoven C et al (2009) Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics 3:169–190Google Scholar
  28. 28.
    Matimba A, Oluka MN, Ebeshi BU et al (2008) Establishment of a biobank and pharmacogenetics database of African populations. Eur J Hum Genet 16:780–783CrossRefGoogle Scholar
  29. 29.
    Nyakutira C, Röshammar D, Chigutsa E et al (2008) High prevalence of the CYP2B6 516G– > T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 64:357–365CrossRefGoogle Scholar
  30. 30.
    Oscason M, Hilderstrand M, Johansson I et al (1997) A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alteractions in enzyme function. Mol Pharmacol 52:1034–1040Google Scholar
  31. 31.
    Thelingwani RS, Zvada SP, Hugues D et al (2009) In vitro and in silico identification and characterisation of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug–drug interactions. Drug Metab Dispos 37:1286–1294CrossRefGoogle Scholar
  32. 32.
    Vazquez ML, Jung H, Sotelo J (1987) Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology 37:1561–1562CrossRefGoogle Scholar
  33. 33.
    Zeldin RK, Petruschke RA (2004) Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 53:4–9CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.African Institute of Biomedical Science & TechnologyHarareZimbabwe

Personalised recommendations

Cite chapter

Buy options